Analysts Set Haemonetics Corporation (NYSE:HAE) PT at $78.89

Shares of Haemonetics Corporation (NYSE:HAE) have been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $78.8889.

A number of research firms have weighed in on HAE. Barrington Research cut their price target on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 12th. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Robert W. Baird set a $67.00 price objective on Haemonetics in a report on Friday, May 8th. Weiss Ratings raised Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, June 25th. Finally, Mizuho lifted their target price on Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th.

Hedge Funds Weigh In On Haemonetics

Several hedge funds and other institutional investors have recently modified their holdings of the company. AQR Capital Management LLC increased its position in Haemonetics by 48.6% during the 4th quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock worth $253,523,000 after purchasing an additional 1,034,226 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Haemonetics by 994.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock valued at $110,615,000 after buying an additional 1,254,035 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Haemonetics by 21.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after buying an additional 233,119 shares in the last quarter. North Peak Capital Management LLC grew its stake in Haemonetics by 204.4% during the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after buying an additional 740,626 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH grew its stake in Haemonetics by 17.3% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 841,017 shares of the medical instruments supplier’s stock worth $47,400,000 after buying an additional 124,020 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Trading Down 0.2%

NYSE HAE opened at $78.03 on Friday. Haemonetics has a 12 month low of $47.31 and a 12 month high of $87.32. The company has a 50-day moving average of $71.49 and a 200-day moving average of $66.12. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The company has a market cap of $3.55 billion, a P/E ratio of 38.63, a P/E/G ratio of 1.58 and a beta of 0.52.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business had revenue of $346.35 million for the quarter, compared to analysts’ expectations of $336.83 million. During the same period last year, the company earned $1.24 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, equities analysts predict that Haemonetics will post 5.21 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.